Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd. is an Israel-based clinical-stage biotechnology company focused on discovering and developing cancer immunotherapies. Founded in 1993, the company uses computational biology and related technologies to identify potential drug targets and develop antibody-based treatments.

Its research centers on immune checkpoint pathways that can affect how the body’s immune system recognizes and attacks tumors. Compugen’s programs have included antibody candidates targeting PVRIG and TIGIT, among other potential therapies.

The company works to advance its drug candidates through clinical development and has collaborated with pharmaceutical companies on research and development. Its activities are focused on oncology, and it does not offer a broad range of commercial medicines.

Key Stats

• Today's Range: $2.04 to $2.12
• 50-Day Range: $1.88 to $2.59
• 52-Week Range: $1.43 to $3.23
• Volume: 209,584 shs
• Average Volume: 242,389 shs
• Market Capitalization: $198.56 million
• P/E Ratio: 5.38
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 64% of companies evaluated by MarketBeat, and ranked 307th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Compugen has a consensus price target of $5.00, representing about 138.1% upside from its current price of $2.10.

Amount of Analyst Coverage

Compugen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Compugen are expected to grow in the coming year, from ($0.29) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is 5.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is 5.38, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.95% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Compugen has recently increased by 0.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Compugen has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Compugen this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

12.22% of the stock of Compugen is held by institutions.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/14/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 75
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $5.00
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +138.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.39
• Trailing P/E Ratio: 5.38
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.34 million
• Net Margins: 47.90%
• Pretax Margin: 47.92%
• Return on Equity: 39.30%
• Return on Assets: 25.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 5.72

Sales & Book Value

• Annual Sales: $72.76 million
• Price / Sales: 2.73
• Cash Flow: $0.37 per share
• Price / Cash Flow: 5.67
• Book Value: $0.88 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 94,550,000
• Free Float: 85,570,000
• Market Cap: $198.56 million
• Optionable: Optionable
• Beta: 2.85